Navigation Links
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Date:3/19/2009

plant seeds to USP and EP standards and finally, we have obtained regulatory approval in the US and Europe to administer SBS 1000 in a phase I/II clinical trial, where our insulin was been found to be biologically active without any unexpected adverse reactions," commented James Szarko, Chief Executive Officer at SemBioSys. "We are continuing optimization work targeted at streamlining the production process to further improve cost of goods."

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI(Milano), a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could ca
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys announces senior management changes
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
5. SemBioSys announces second quarter 2008 financial and operational results
6. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
9. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
10. SemBioSys announces first quarter 2008 financial and operational results
11. SemBioSys receives milestone payments from AVAC Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
(Date:9/15/2014)... -- iVinci Health LLC, the company behind the healthcare industry,s ... as VisitPay®, has successfully closed $5 million in new ... new extension to VisitPay® – an online Payment and ... for patients to manage their medical bills and set-up ... families. The new round of funding, which ...
(Date:9/15/2014)... AUSTIN, Texas , Sept. 15, 2014 The ... changes in climate, says a new article published by the ... Ahmed , PhD, on climate change and its effects on ... part of an extensive study conducted by Dr. Ahmed in ... China and has implications for the future ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... for Nanotechnology (LCN) have discovered electronic stripes, called ,charge ... that make up a graphitic superconductor. This is the ... and the finding is likely to have profound implications ... scientists believe will play a key role in the ...
... Inc. (NYSE: WPI ) today announced that ... the United States Food and Drug Administration for its ... and 0.02 mg ethinyl estradiol), a generic version of ... in patent litigation with Bayer concerning this product.  ...
... HAYWARD, Calif., Nov. 29, 2011 Metabolex, Inc., ... development of proprietary new medicines for the treatment ... has been recognized in Windhover,s "Top 10 most ... a potential best-in-class treatment for gout that not ...
Cached Biology Technology:Graphene earns its stripes 2Watson's Generic Yaz(R) Receives FDA Approval 2Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 2Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 3
(Date:9/15/2014)... produced naturally across all kingdoms of life and constitute ... range of biological activities. The presence of halogen substituents ... their molecular properties. , One of the ... the late-stage, site-specific incorporation of a halogen atom into ... bond (one of the most inert chemical bonds known ...
(Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
(Date:9/15/2014)... that affect hearing and cognitive function may play roles ... and perceive rhythm, pitch, timbre, tone durations, and formal ... BioEssays article explain that extremes in musical aptitude ... the majority of individuals having moderate aptitude. , "This ... to several underlying genes, and it is influenced to ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... propose ever-larger conservation areas in the tropics, ones that ... banding together with their community leaders who ultimately determine ... parts of the world., "When people sacrifice to conserve, ... Christie, University of Washington associate professor of marine affairs ...
... Alexandria, Va. The American Association for Dental ... 2010 AADR Neal W. Chilton Fellowship in Clinical Research ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... and associate director of the Delta Dental of Kentucky ...
... the first-ever data to show that the enzyme calcineurin is ... and that loss of the protein leads to heart problems ... in the Journal of Biological Chemistry as the ... research was led by scientists at Cincinnati Children,s Hospital Medical ...
Cached Biology News:Local social dynamics key to success of tropical marine conservation areas 2Scientists identify critical enzyme in healthy heart function 2